Clinical Trial Design Considerations for the Development of Disease-Modifying Therapies for Type 1 Diabetes
The landscape of type 1 diabetes (T1D) research is undergoing a quiet revolution, shifting focus from merely managing blood glucose levels to altering the underlying autoimmune trajectory of the condition. For nearly a century, the standard of care for type 1 diabetes has relied entirely on exogenous insulin replacement—a life-saving intervention, but one that leaves patients vulnerable to chronic glycemic fluctuations, long-term microvascular and macrovascular complications, and the relentless daily burden of disease management. Today, scientific advancements are paving the way for disease-modifying therapies (DMTs) designed to intervene at the root cause of the disease: the autoimmune destruction of insulin-producing pancreatic beta cells.
To accelerate the delivery of these transformative treatments to patients, Breakthrough T1D—a leading global type 1 diabetes research and advocacy organization—has published a landmark manuscript outlining strategic frameworks for clinical trial design. Published in the October 2026 issue of the peer-reviewed journal Diabetes, the paper, titled “Clinical Trial Design Considerations for the Development of Disease-Modifying Therapies for Type 1 Diabetes,” was co-authored by prominent clinical experts and internal research staff. The publication serves as an urgent call to action, offering a comprehensive roadmap for pharmaceutical developers, academic researchers, and regulatory agencies to streamline clinical trials, overcome historical bottlenecks, and bring a diverse array of therapeutic choices to the global diabetes community.
The urgency behind this methodological shift is clear. While numerous experimental DMTs have demonstrated a robust ability to protect and preserve beta cell function in early-phase trials, only a fraction of these candidates successfully advance to pivotal phase 3 clinical trials—the final, rigorous stage of testing required before seeking formal approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA). By addressing the structural inefficiencies that have historically plagued autoimmune drug development, this new roadmap aims to drastically reduce the time, financial expenditure, and participant burdens associated with bringing DMTs to market.
Understanding the Imperative for Beta Cell Preservation
To appreciate the gravity of the new publication, one must examine the physiological stakes of type 1 diabetes. The disease is characterized by an autoimmune assault in which the body’s immune system mistakenly identifies pancreatic beta cells as foreign invaders and destroys them. When individuals are diagnosed with clinical stage 3 T1D, they have typically lost a significant portion of their functional beta cell mass, forcing them to rely on lifelong insulin delivery via multiple daily injections or automated insulin delivery systems.
However, clinical research has consistently demonstrated that preserving even a fraction of endogenous (natural) insulin production yields profound clinical benefits. The preservation of residual beta cell function—frequently measured via C-peptide levels, a byproduct created when the pancreas produces insulin—is directly correlated with improved glycemic control. Patients retaining some natural insulin production experience significantly fewer dangerous hypoglycemic (low blood sugar) events, exhibit more stable HbA1c levels, and face a substantially reduced risk of debilitating long-term complications, such as retinopathy, nephropathy, and neuropathy. Furthermore, metabolic management becomes measurably less complex. As medical professionals frequently emphasize, the most physiologically compatible insulin is the insulin that the human body manufactures on its own.
A Historical Bottleneck in Drug Development
Despite these clear physiological advantages, the clinical development pipeline for T1D disease-modifying therapies has faced severe obstacles. Historically, regulatory approval pathways for diabetes therapeutics have relied heavily on macro-endpoints, such as the total daily insulin dose required or long-term preservation of overall glycemic control over extended multi-year periods. These traditional endpoints demand large patient cohorts, prolonged follow-up windows, and extensive financial resources.
Consequently, many promising candidate therapies stall after phase 2 trials. Drug developers face daunting financial and operational risks when attempting to scale trials to the massive sizes traditionally required by regulators. This friction has slowed the pace of innovation, leaving patients with limited therapeutic avenues. Up to this point, only one DMT—teplizumab (sold under the brand name Tzield)—has secured regulatory approval. Teplizumab, an anti-CD3 monoclonal antibody, was approved by the FDA to delay the onset of stage 3 T1D in individuals with stage 2 disease, and was subsequently cleared for recently diagnosed stage 3 T1D patients.
While the introduction of teplizumab represents a historic milestone for the diabetes community, healthcare providers and patient advocates stress that a single approved therapeutic option is insufficient for a complex, heterogeneous disease like type 1 diabetes. Just as oncology and rheumatology rely on diverse portfolios of targeted therapies to address varying patient profiles, the T1D community requires a broad array of DMTs with distinct mechanisms of action. This diversity ensures that clinicians can tailor treatments to individual immune profiles, disease stages, and personal preferences.
Strategic Solutions for Modern Clinical Trials
To clear the path from early discovery to phase 3 evaluation, the Breakthrough T1D publication outlines five foundational pillars for optimizing clinical trial design. These strategies are designed to modernize how trials are conceptualized, executed, and evaluated by regulatory agencies.
Matching Mechanisms with Patient Populations
Type 1 diabetes is not a monolithic disease; its progression and immunological signatures vary significantly from person to person. The new publication stresses the critical importance of matching a drug’s specific mechanism of action with the appropriate patient population. Depending on whether an individual is in early pre-symptomatic stages (stage 1 or stage 2) or has recently entered clinical diagnosis (stage 3), their immune landscape differs. Furthermore, genetic background and distinct immune cell profiles dictate how a patient will respond to a specific immunomodulatory agent. Precision medicine approaches must be integrated into trial recruitment to ensure therapies are tested in the cohorts most likely to derive clinical benefit.
Leveraging Combination Therapies
Just as modern oncology protocols frequently employ multi-drug regimens to attack tumors through complementary pathways, the future of T1D treatment likely lies in combination therapies. Administering two or more DMTs with distinct mechanisms of action simultaneously—or in strategic sequence—can potentially halt autoimmune destruction more effectively than any single agent used in isolation. As a prime example, the ongoing WAVE T1D clinical trial is currently evaluating the synergistic potential of combining verapamil, a blood pressure medication known to reduce endoplasmic reticulum stress in beta cells, with antithymocyte globulin (ATG), an immunosuppressive agent that targets the specific T cells responsible for beta cell destruction.
Repurposing Approved Autoimmune Therapies
Developing a novel pharmaceutical compound from scratch requires billions of dollars and decades of preclinical safety testing. To circumvent this delay, researchers are increasingly looking to repurpose therapies that have already gained regulatory approval for other autoimmune conditions, such as rheumatoid arthritis, psoriasis, or alopecia. Because the safety profiles, pharmacokinetic properties, and dosing parameters of these drugs are already established in human populations, researchers can bypass duplicative early-stage safety studies. A notable example of this strategy is baricitinib, a Janus kinase (JAK) inhibitor currently being evaluated in two Breakthrough T1D-funded phase 3 clinical trials to determine its efficacy in preserving beta cell function and delaying disease progression in newly diagnosed individuals.
Adopting Efficient Surrogate Endpoints
Perhaps the most critical recommendation in the new publication centers on the adoption of validated surrogate endpoints. Traditional clinical trials have often required years of observation to measure long-term health outcomes. However, biomarkers such as C-peptide levels have emerged as reliable predictors of clinical benefit. By convincing regulatory bodies to accept C-peptide preservation as a validated surrogate endpoint for early approval pathways, clinical trials can be completed in a fraction of the time. This regulatory modernization allows researchers to assess the efficacy of a drug much faster, accelerating the timeline for drugs to move through the pipeline without compromising patient safety.
Centering the Lived Experience of Patients
Finally, the roadmap emphasizes the integration of patient-centric design principles into clinical trial execution. Historically, clinical trial protocols have been drafted strictly from a clinical or academic perspective, occasionally creating recruitment and retention hurdles. By actively incorporating the voices, preferences, and lived experiences of individuals with type 1 diabetes and their families into protocol design, researchers can construct trials that minimize patient burden, enhance retention rates, and ultimately deliver therapies that align with real-world lifestyle needs.
The Current Pipeline and Broader Implications
The release of this clinical trial design framework arrives at a time of unprecedented scientific momentum. Clinical data has now confirmed that at least ten different disease-modifying therapies have successfully preserved or slowed the decline of beta cell function following a type 1 diabetes diagnosis, as quantified by sustained C-peptide production. Beyond these ten clinical-stage assets, a robust pipeline of preclinical candidates shows immense promise in laboratory models.
The primary obstacle is no longer a lack of scientific discovery, but rather the structural friction of the clinical evaluation process. By standardizing these methodological recommendations across the biopharmaceutical industry, stakeholders hope to bridge the gap between early-stage laboratory success and pivotal phase 3 trials.
From a macroeconomic and public health perspective, the successful translation of these DMTs could fundamentally alter the trajectory of type 1 diabetes care. Delaying the onset of clinical symptoms or preserving endogenous insulin production for years—or decades—reduces the lifetime incidence of costly acute and chronic complications, lessens the mental health burden associated with round-the-clock glycemic management, and lowers overall healthcare expenditures.
As researchers, regulators, and industry leaders digest the recommendations laid out in the October 2026 issue of Diabetes, the global T1D community stands on the precipice of a new era. With coordinated action, modernized regulatory pathways, and smart trial architectures, the scientific community is well-positioned to transform disease-modifying therapies from experimental concepts into accessible, everyday clinical realities for millions of individuals living with type 1 diabetes worldwide.
